Regulatory Roles of Protein Kinases in Cytomegalovirus Replication

Advances in Virus Research

Volumn 80, Issue , 2011, Pages 69-101

  Marschall, Manfred ^a   Feichtinger, Sabine ^a   Milbradt, Jens ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cytomegalovirus replication; Kinase inhibitors as antiviral drugs; Multi protein complexes; Protein kinases; Regulatory protein phosphorylation; Viral kinase pUL97; Viral nuclear egress

Indexed keywords

CYCLIN DEPENDENT KINASE; GANCICLOVIR KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE C;

ANIMAL; BOOK; CELL LINE; CYTOMEGALOVIRUS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HERPES VIRUS INFECTION; HUMAN; METABOLISM; NUCLEAR LAMINA; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RETINOBLASTOMA; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CELL LINE; CYCLIN-DEPENDENT KINASES; CYTOMEGALOVIRUS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRIDAE INFECTIONS; HUMANS; NUCLEAR LAMINA; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE C; RETINOBLASTOMA; VIRUS REPLICATION;

EID: 79960216982     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385987-7.00004-X     Document Type: Book

References (155)

1. Adler S.P., Nigro G., Pereira L. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin. Perinatol. 2007, 31:10-18.
2. Andrei G., De Clercq E., Snoeck R. Drug targets in cytomegalovirus infection. Infect. Disord. Drug Targets 2009, 9:201-222.
3. AuCoin D.P., Smith G.B., Meiering C.D., Mocarski E.S. Betaherpesvirus-conserved cytomegalovirus tegument protein ppUL32 (pp 150) controls cytoplasmic events during virion maturation. J. Virol. 2006, 80:8199-8210.
4. Baek M.C., Krosky P.M., Pearson A., Coen D.M. Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase. J. Virol. 2004, 324:184-193.
5. Bain M., Sinclair J. The S phase of the cell cycle and its perturbation by human cytomegalovirus. Rev. Med. Virol. 2007, 17:423-434.
6. Becke S., Fabre-Mersseman V., Aue S., Auerochs S., Sedmak T., Wolfrum U., Strand D., Marschall M., Plachter B., Reyda S. Modification of the major tegument protein pp 65 of 1 human cytomegalovirus inhibits viral growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells. J. Gen. Virol. 2010, 91:2531-2541.
7. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46:2365-2372.
8. Bjerke S.L., Roller R.J. Roles for herpes simplex virus type 1 UL34 and US3 proteins in disrupting the nuclear lamina during herpes simplex virus type 1 egress. Virology 2006, 347:261-276.
9. Bresnahan W.A., Boldogh I., Thompson E.A., Albrecht T. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology 1996, 224:150-160.
10. Bresnahan W.A., Boldogh I., Chi P., Thompson E.A., Albrecht T. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 1997, 231:239-247.
11. Bubeck A., Wagner M., Ruzsics Z., Lötzerich M., Iglesias M., Singh I.R., Koszinowski U.H. Comprehensive mutational analysis of a herpesvirus gene in the viral genome context reveals a region essential for virus replication. J. Virol. 2004, 78:8026-8035.
12. Buchkovich N.J., Maguire T.G., Alwine J.C. Role of the endoplasmic reticulum chaperone BiP, SUN domain proteins, and dynein in altering nuclear morphology during human cytomegalovirus infection. J. Virol. 2010, 84:7005-7017.
13. Buser C., Walther P., Mertens T., Michel D. Cytomegalovirus primary envelopment occurs at large infoldings of the inner nuclear membrane. J. Virol. 2007, 81:3042-3048.
14. Camozzi D., Pignatelli S., Valvo C., Lattanzi G., Capanni C., Dal Monte P., Landini M.P. Remodelling of the nuclear lamina during human cytomegalovirus infection: Role of the viral proteins pUL50 and pUL53. J. Gen. Virol. 2008, 89:731-740.
15. Canduri F., Perez P.C., Caceres R.A., de Azevedo W.F. CDK9 a potential target for drug development. Med. Chem. 2008, 4:210-218.
16. Carnero A., Hannon G.J. The INK4 family of CDK inhibitors. Curr. Top. Microbiol. Immunol. 1998, 227:43-55.
17. Chang Y.E., Van Sant C., Krug P.W., Sears A.E., Roizman B. The null mutant of the UL31 gene of herpes simplex virus 1: Construction and phenotype in infected cells. J. Virol. 1997, 71:8307-8315.
18. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008, 18:233-246.
19. Cohen P. Protein kinases-The major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 2002, 4:309-315.
20. Cook A., Bono F., Jinek M., Conti E. Structural biology of nucleocytoplasmic transport. Annu. Rev. Biochem. 2007, 76:647-671.
21. Cross T., Griffiths G., Deacon E., Sallis R., Gough M., Watters D., Lord J.M. PKC-delta is an apoptotic lamin kinase. Oncogene 2000, 19:2331-2337.
22. Cruzalegui F. Protein kinases: From targets to anti-cancer drugs. Ann. Pharm. Fr. 2010, 68:254-259.
23. Das S., Vasanji A., Pellett P.E. Three-dimensional structure of the human cytomegalovirus cytoplasmic virion assembly complex includes a reoriented secretory apparatus. J. Virol. 2007, 81:11861-11869.
24. Dechat T., Pfleghaar K., Sengupta K., Shimi T., Shumaker D.K., Solimando L., Goldman R.D. Nuclear lamins: Major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008, 22:832-853.
25. Dynlacht B.D., Flores O., Lees J.A., Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 1994, 8:1772-1786.
26. Eid A.J., Razonable R.R. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70:965-981.
27. Espinoza F.H., Farrell A., Erdjument-Bromage H., Tempst P., Morgan D.O. A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science 1996, 273:1714-1717.
28. Feichtinger S., Stamminger T., Müller R., Graf L., Klebl B., Eickhoff J., Marschall M. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1. J. Gen. Virol. 2011, 30. Epub ahead of print.
29. Filippakis H., Spandidos D.A., Sourvinos G. Herpesviruses: Hijacking the Ras signaling pathway. Biochim. Biophys. Acta 2010, 1803:777-785.
30. Fisher R.P., Morgan D.O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994, 78:713-724.
31. Fuchs W., Klupp B.G., Granzow H., Osterrieder N., Mettenleiter T.C. The interacting UL31 and UL34 gene products of pseudorabies virus are involved in egress from the host-cell nucleus and represent components of primary enveloped but not mature virions. J. Virol. 2002, 76:364-378.
32. Geng Y., Eaton E.N., Picon M., Roberts J.M., Lundberg A.S., Gifford A., Sardet C., Weinberg R.A. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 1996, 12:1173-1180.
33. Gershburg E., Pagano J.S. Conserved herpesvirus protein kinases. Biochim. Biophys. Acta 2007, 1784:203-212.
34. Gill R.B., Frederick S.L., Hartline C.B., Chou S., Prichard M.N. Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol. J. 2009, 6:9.
35. Goekjian P.G., Jirousek M.R. Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development. Curr. Med. Chem. 1999, 6:877-903.
36. Goldberg M.W., Fiserova J., Huttenlauch I., Stick R. A new model for nuclear lamina organization. Biochem. Soc. Trans. 2008, 36:1339-1343.
37. Goldman R.D., Gruenbaum Y., Moir R.D., Shumaker D.K., Spann T.P. Nuclear lamins: Building blocks of nuclear architecture. Genes Dev. 2002, 16:533-547.
38. Goldsmith E.J., Akella R., Min X., Zhou T., Humphreys J.M. Substrate and docking interactions in serine/threonine protein kinases. Chem. Rev. 2007, 107:5065-5081.
39. Gruenbaum Y., Margalit A., Goldman R.D., Shumaker D.K., Wilson K.L. The nuclear lamina comes of age. Nat. Rev. Mol. Cell Biol. 2005, 6:21-31.
40. Hamirally S., Kamil J.P., Ndassa-Colday Y.M., Lin A.J., Jahng W.J., Baek M.C., Noton S., Silva L.A., Simpson-Holley M., Knipe D.M., Golan D.E., Marto J.A., et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 2009, 5:e1000275.
41. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
42. Hardie G., Hanks S. Protein-serine kinases. The Protein Kinase Facts Book 1995, 58-64. Academic Press Ltd. Elsevier Inc., Missouri, USA, 80-89. G. Hardie, S. Hanks (Eds.).
43. Hayashi M.L., Blankenship C., Shenk T. Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle. Proc. Natl Acad. Sci. USA 2000, 97:2692-2696.
44. Heald R., McKeon F. Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis. Cell 1990, 61:579-589.
45. Hengst L., Reed S.I. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol. 1998, 227:25-41.
46. Heredia A., Davis C., Bamba D., Le N., Gwarzo M.Y., Sadowska M., Gallo R.C., Redfield R.R. Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 2005, 19:2087-2095.
47. Herget T., Marschall M. Recent developments in anti-herpesviral combination therapy based on protein kinase inhibitors. New Concepts of Antiviral Therapy 2006, 351-371. Springer, London, UK. A. Holzenburg, E. Bogner (Eds.).
48. Herget T., Freitag M., Morbitzer M., Stamminger T., Marschall M. A novel chemical class of pUL97 protein kinase-specific inhibitors with strong anti-cytomegaloviral activity. Antimicrob. Agents Chemother. 2004, 48:4154-4162.
49. Hinds P.W., Mittnacht S., Dulic V., Arnold A., Reed S.I., Weinberg R.A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992, 70:993-1006.
50. Hume A.J., Finkel J.S., Kamil J.P., Coen D.M., Culbertson M.R., Kalejta R.F. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 2008, 320:797-799.
51. Ishov A.M., Stenberg R.M., Maul G.G. Human cytomegalovirus immediate early interaction with host nuclear structures: Definition of an immediate transcript environment. J. Cell Biol. 1997, 138:5-16.
52. Isobe K., Gohara R., Ueda T., Takasaki Y., Ando S. The last twenty residues in the head domain of mouse lamin A contain important structural elements for formation of head-to-tail polymers in vitro. Biosci. Biotechnol. Biochem. 2007, 71:1252-1259.
53. Jault F.M., Jault J.M., Ruchti F., Fortunato E.A., Clark C., Corbeil J., Richman D.D., Spector D.H. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J. Virol. 1995, 69:6697-6704.
54. Kapasi A.J., Spector D.H. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. J. Virol. 2008, 82:394-407.
55. Kapinos L.E., Schumacher J., Mücke N., Machaidze G., Burkhard P., Aebi U., Strelkov S.V., Herrmann H. Characterization of the head-to-tail overlap complexes formed by human lamin A, B1 and B2 "half-minilamin" dimers. J. Mol. Biol. 2010, 396:719-731.
56. Kato J., Matsushime H., Hiebert S.W., Ewen M.E., Sherr C.J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993, 7:331-342.
57. Kawaguchi Y., Kato K. Protein kinases conserved in herpesviruses potentially share a function mimicking the cellular protein kinase cdc2. Rev. Med. Virol. 2003, 13:331-340.
58. Kawaguchi Y., Matsumura T., Roizman B., Hirai K. Cellular elongation factor 1δ is modified in cells infected with representative alpha-, beta-, or gammaherpesviruses. J. Virol. 1999, 73:4456-4460.
59. Klupp B.G., Granzow H., Fuchs W., Keil G.M., Finke S., Mettenleiter T.C. Vesicle formation from the nuclear membrane is induced by coexpression of two conserved herpesvirus proteins. Proc. Natl Acad. Sci. USA 2007, 2007(104):7241-7246.
60. Krosky P.M., Baek M.-C., Jahng W.J., Barrera I., Harvey R.J., Biron K.K., Coen D.M., Sethna P.B. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 2003, 77:7720-7727.
61. Kuny C.V., Chinchilla K., Culbertson M.R., Kalejta R.F. Cyclin-dependent kinase-like function is shared by the beta- and gamma- subset of the conserved herpesvirus protein kinases. PLoS Pathog. 2010, 6:e1001092.
62. Lake C.M., Hutt-Fletcher L.M. The Epstein-Barr virus BFRF1 and BFLF2 proteins interact and coexpression alters their cellular localization. Virology 2004, 320:99-106.
63. Lee C.P., Chen M.R. Escape of herpesviruses from the nucleus. Rev. Med. Virol. 2010, 20:214-230.
64. Lee C.P., Huang Y.H., Lin S.F., Chang Y., Chang Y.H., Takada K., Chen M.R. Epstein-Barr virus BGLF4 kinase induces disassembly of the nuclear lamina to facilitate virion production. J. Virol. 2008, 82:11913-11926.
65. Leuzinger H., Ziegler U., Schraner E.M., Fraefel C., Glauser D.L., Heid I., Ackermann M., Mueller M., Wild P. Herpes simplex virus 1 envelopment follows two diverse pathways. J. Virol. 2005, 79:13047-13059.
66. Liang L., Baines J.D. Identification of an essential domain in the herpes simplex virus 1 UL34 protein that is necessary and sufficient to interact with UL31 protein. J. Virol. 2005, 79:3797-3806.
67. Lippens G., Landrieu I., Smet C. Molecular mechanisms of the phospho-dependent prolyl cis/trans isomerase Pin1. FEBS J. 2007, 274:5211-5222.
68. Lischka P., Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 2008, 8:541-548.
69. Lischka P., Rosorius O., Trommer E., Stamminger T. A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69. EMBO J. 2001, 20:7271-7283.
70. Lischka P., Toth Z., Thomas M., Mueller R., Stamminger T. The UL69 transactivator protein of human cytomegalovirus interacts with DEXD/H-Box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA. Mol. Cell. Biol. 2006, 26:1631-1643.
71. Lischka P., Thomas M., Toth Z., Mueller R., Stamminger T. Multimerization of human cytomegalovirus regulatory protein UL69 via a domain that is conserved within its herpesvirus homologues. J. Gen. Virol. 2007, 88:405-410.
72. Lötzerich M., Ruzsics Z., Koszinowski U.H. Functional domains of murine cytomegalovirus nuclear egress protein M53/p38. J. Virol. 2006, 80:73-84.
73. Lu M., Shenk T. Human cytomegalovirus UL69 protein induces cells to accumulate in G1 phase of the cell cycle. J. Virol. 1999, 73:676-683.
74. Lu K.P., Zhou X.Z. The prolyl isomerase PIN1: A pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:904-916.
75. Lu K.P., Finn G., Lee T.H., Nicholson L.K. Prolyl cis-trans isomerization as a molecular timer. Nat. Chem. Biol. 2007, 3:619-629.
76. Mailand N., Falck J., Lukas C., Syljuasen R.G., Welcker M., Bartek J., Lukas J. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000, 288:1425-1429.
77. Majello B., Napolitano G. Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. Front. Biosci. 2001, 6:D1358-D1368.
78. Margalit A., Vlcek S., Gruenbaum Y., Foisner R. Breaking and making of the nuclear envelope. J. Cell. Biochem. 2005, 95:454-465.
79. Marschall M., Stamminger T. Molecular targets for antiviral therapy of cytomegalovirus infections. Future Microbiol. 2009, 4:731-742.
80. Marschall M., Stein-Gerlach M., Freitag M., Kupfer R., van den Bogaard M., Stamminger T. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J. Gen. Virol. 2001, 82:1439-1450.
81. Marschall M., Stein-Gerlach M., Freitag M., Kupfer R., van den Bogaard M., Stamminger T. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle of antiviral therapy. J. Gen. Virol. 2002, 83:1013-1023.
82. Marschall M., Freitag M., Suchy P., Romaker D., Kupfer R., Hanke M., Stamminger T. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 2003, 311:60-71.
83. Marschall M., Marzi A., aus dem Siepen P., Jochmann R., Kalmer M., Auerochs S., Lischka P., Leis M., Stamminger T. Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J. Biol. Chem. 2005, 280:33357-33367.
84. Maul G.G., Negorev D. Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle. Med. Microbiol. Immunol. 2008, 197:241-249.
85. McConnell B.B., Gregory F.J., Stott F.J., Hara E., Peters G. Induced expression of p16(INK4a) inhibits both. Mol. Cell. Biol. 1999, 19:1981-1989.
86. McGeoch D.J., Rixon F.J., Davison A.J. Topics in herpesvirus genomics and evolution. Virus Res. 2006, 117:90-104.
87. Meinhart A., Kamenski T., Hoeppner S., Baumli S., Cramer P. A structural perspective of CTD function. Genes Dev. 2005, 19:1401-1415.
88. Mettenleiter T.C. Budding events in herpesvirus morphogenesis. Virus Res. 2004, 106:167-180.
89. Mettenleiter T.C., Klupp B.G., Granzow H. Herpesvirus assembly: An update. Virus Res. 2009, 143:222-234.
90. Meyerson M., Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 1994, 14:2077-2086.
91. Michel D., Mertens T. The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: Impact on virus and host. Biochim. Biophys. Acta 2004, 1697:169-180.
92. Milbradt J., Auerochs S., Marschall M. Cytomegaloviral proteins pUL50 and pUL53 are associated with the nuclear lamina and interact with cellular protein kinase C. J. Gen. Virol. 2007, 88:2642-2650.
93. Milbradt J., Auerochs S., Sticht H., Marschall M. Cytomegaloviral proteins that associate with the nuclear lamina: Components of a postulated nuclear egress complex. J. Gen. Virol. 2009, 90:579-590.
94. Milbradt J., Webel R., Auerochs S., Sticht H., Marschall M. Novel mode of phosphorylation-triggered reorganization of the nuclear lamina during nuclear egress of human cytomegalovirus. J. Biol. Chem. 2010, 285:13979-13989.
95. Mocarski E., Shenk T., Pass R.F. Cytomegaloviruses. Fields Virology 2007, 2701-2772. Lippincott Williams & Wilkins, Philadelphia. 5th edn. D.M. Knipe, P.M. Howley (Eds.).
96. Morgan D.O. Principles of CDK regulation. Nature 1995, 374:131-134.
97. Morgan D.O. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13:261-291.
98. Muranyi W., Haas J., Wagner M., Krohne G., Koszinowski U.H. Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science 2002, 297:854-857.
99. Mylonis I., Drosou V., Brancorsini S., Nikolakaki E., Sassone-Corsi P., Giannakouros T. Temporal association of protamine 1 with the inner nuclear membrane protein lamin B receptor during spermiogenesis. J. Biol. Chem. 2004, 279:11626-11631.
100. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990, 344:503-508.
101. O'Farrell P.H. Triggering the all-or-nothing switch into mitosis. Trends Cell Biol. 2001, 11:512-519.
102. Orzaez M., Gortat A., Mondragon L., Bachs O., Perez-Paya E. ATP-noncompetitive inhibitors of CDK-cyclin complexes. ChemMedChem 2009, 4:19-24.
103. Panté N., Kann M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Mol. Biol. Cell 2002, 13:425-434.
104. Park R., Baines J.D. Herpes simplex virus type 1 infection induces activation and recruitment of protein kinase C to the nuclear membrane and increased phosphorylation of lamin B. J. Virol. 2006, 80:494-504.
105. Pavletich N.P. Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 1999, 287:821-828.
106. Pellett P.E., Roizman B. The family herpesviridae: A brief introduction. Fields Virology 2007, 2479-2500. Lippincott Williams & Wilkins, Philadelphia. 5th edn. D.M. Knipe, P.M. Howley (Eds.).
107. Peter M., Nakagawa J., Dorée M., Labbé J.C., Nigg E.A. In vitro disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by cdc2 kinase. Cell 1990, 61:591-602.
108. Peter M., Heitlinger E., Häner M., Aebi U., Nigg E.A. Disassembly of in vitro formed lamin head-to-tail polymers by CDC2 kinase. EMBO J. 1991, 10:1535-1544.
109. Pines J., Hunter T. Human cell division: The involvement of cyclins A and B1, and multiple cdc2s. Cold Spring Harb. Symp. Quant. Biol. 1991, 56:449-463.
110. Prichard M.N. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 2009, 19:215-229.
111. Prichard M.N., Gao N., Jairath S., Mulamba G., Krosky P., Coen D.M., Parker B.O., Pari G.S. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 1999, 73:5663-5670.
112. Prichard M.N., Sztul E., Daily S.L., Perry A.L., Frederick S.L., Gill R.B., Hartline C.B., Streblow D.N., Varnum S.M., Smith R.D., Kern E.R. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J. Virol. 2008, 82:5054-5067.
113. Rechter S., Scott G.M., Eickhoff J., Zielke K., Auerochs S., Müller R., Stamminger T., Rawlinson W.D., Marschall M. Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 to modulate its nuclear localization and activity. J. Biol. Chem. 2009, 284:8605-8613.
114. Reinberg D., Orphanides G., Ebright R., Akoulitchev S., Carcamo J., Cho H., Cortes P., Drapkin R., Flores O., Ha I., et al. The RNA polymerase II general transcription factors: Past, present, and future. Cold Spring Harb. Symp. Quant. Biol. 1998, 63:83-103.
115. Reynolds A.E., Ryckman B.J., Baines J.D., Zhou Y., Liang L., Roller R.J. UL31 and UL34 proteins of herpes simplex virus type 1 form a complex that accumulates at the nuclear rim and is required for envelopment of nucleocapsids. J. Virol. 2001, 75:8803-8817.
116. Reynolds A.E., Liang L., Baines J.D. Conformational changes in the nuclear lamina induced by herpes simplex virus type 1 require genes UL31 and UL34. J. Virol. 2004, 78:5564-5575.
117. Robles-Flores M., Rendon-Huerta E., Gonzalez-Aguilar H., Mendoza-Hernandez G., Islas S., Mendoza V., Ponce-Castaneda M.V., Gonzalez-Mariscal L., Lopez-Casillas F. p32 (gC1qBP) is a general protein kinase C (PKC)-binding protein; interaction and cellular localization of P32-PKC complexes in ray hepatocytes. J. Biol. Chem. 2002, 277:5247-5255.
118. Roller R.J., Zhou Y., Schnetzer R., Ferguson J., DeSalvo D. Herpes simplex virus type 1 UL34 gene product is required for viral envelopment. J. Virol. 2000, 74:117-129.
119. Romaker D., Schregel V., Maurer K., Auerochs S., Marzi A., Sticht H., Marschall M. Analysis of the structure-activity relationship of four herpesviral UL97 subfamily protein kinases reveals partial but not full functional conservation. J. Med. Chem. 2006, 49:7044-7053.
120. Russo A.A., Jeffrey P.D., Pavletich N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3:696-700.
121. Salvant B.S., Fortunato E.A., Spector D.H. Cell cycle dysregulation by human cytomegalovirus: Influence of the cell cycle phase at the time of infection and effects on cyclin transcription. J. Virol. 1998, 72:3729-3741.
122. Sam M.D., Evans B.T., Coen D.M., Hogle J.M. Biochemical, biophysical, and mutational analyses of subunit interactions of the human cytomegalovirus nuclear egress complex. J. Virol. 2009, 83:2996-3006.
123. Sampaio K.L., Cavignac Y., Stierhof Y.D., Sinzger C. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J. Virol. 2005, 79:2754-2767.
124. Sanchez V., Spector D.H. Virology. CMV makes a timely exit. Science 2002, 297:778-779.
125. Sanchez V., Spector D.H. Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J. Virol. 2006, 80:5886-5896.
126. Sanchez V., Greis K.D., Sztul E., Britt W.J. Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: Characterization of a potential site of virus assembly. J. Virol. 2000, 74:975-986.
127. Sanchez V., McElroy A.K., Spector D.H. Mechanisms governing maintenance of Cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus. J. Virol. 2003, 77:13214-13224.
128. Sanchez V., McElroy A.K., Yen J., Tamrakar S., Clark C.L., Schwartz R.A., Spector D.H. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J. Virol. 2004, 78:11219-11232.
129. Schang L.M. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs. Antivir. Chem. Chemother. 2001, 12(Suppl. 1):157-178.
130. Schang L.M. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Rev. Anti. Infect. Ther. 2006, 4:953-956.
131. Schang L.M., St.Vincent M.R., Lacasse J.J. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir. Chem. Chemother. 2006, 17:293-320.
132. Schleiss M., Eickhoff J., Auerochs S., Leis M., Abele S., Rechter S., Choi Y., Anderson J., Scott G., Rawlinson W., Michel D., Ensminger S., et al. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res. 2008, 79:49-61.
133. Schnee M., Ruzsics Z., Bubeck A., Koszinowski U.H. Common and specific properties of herpesvirus UL34/UL31 protein family members revealed by protein complementation assay. J. Virol. 2006, 80:11658-11666.
134. Schregel V., Auerochs S., Jochmann R., Maurer K., Stamminger T., Marschall M. Mapping of a self-interaction domain of the cytomegalovirus protein kinase pUL97. J. Virol. 2007, 88:395-404.
135. Sherr C.J. D-type cyclins. Trends Biochem. Sci. 1995, 20:187-190.
136. Shugar D. Inhibitors of protein kinases. Biochim. Biophys. Acta 2010, 1804:427-428.
137. Storz P., Hausser A., Link G., Dedio J., Ghebrehiwet B., Pfizenmaier K., Johannes F.J. Protein kinase C μ is regulated by the multifunctional chaperon protein p32. J. Biol. Chem. 2000, 275:24601-24607.
138. Takeda D.Y., Dutta A. DNA replication and progression through S phase. Oncogene 2005, 24:2827-2843.
139. Tamrakar S., Kapasi A.J., Spector D.H. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7. J. Virol. 2005, 79:15477-15493.
140. Thomas M., Rechter S., Milbradt J., Auerochs S., Müller R., Stamminger T., Marschall M. Cytomegaloviral protein kinase pUL97 interacts with the nuclear mRNA export factor pUL69 to modulate its intranuclear localization and activity. J. Gen. Virol. 2009, 90:567-578.
141. Thompson L.J., Fields A.P. betaII protein kinase C is required for the G2/M phase transition of cell cycle. J. Biol. Chem. 1996, 271:15045-15053.
142. Toth Z., Stamminger T. The human cytomegalovirus regulatory protein UL69 and its effect on mRNA export. Front. Biosci. 2008, 13:2939-2949.
143. Toth Z., Lischka P., Stamminger T. RNA-binding of the human cytomegalovirus transactivator protein UL69, mediated by arginine-rich motifs, is not required for nuclear export of unspliced RNA. Nucleic Acids Res. 2006, 34:1237-1249.
144. Turcotte S., Letellier J., Lippé R. Herpes simplex virus type 1 capsids transit by the trans-Golgi network, where viral glycoproteins accumulate independently of capsid egress. J. Virol. 2005, 79:8847-8860.
145. van Zeijl M., Fairhurst J., Baum E.Z., Sun L., Jones T.R. The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. Virology 1997, 231:72-80.
146. Verdecia M.A., Bowman M.E., Lu K.P., Hunter T., Noel J.P. Structural basis for phosphoserine-proline recognition by group IV WW domains. Nat. Struct. Biol. 2000, 7:639-643.
147. Ward G.E., Kirschner M.W. Identification of cell cycle-regulated phosphorylation sites on nuclear lamin C. Cell 1990, 61:561-577.
148. Webel R., Milbradt J., Auerochs S., Schregel V., Held C., Nöbauer K., Razzazi-Fazeli E., Jardin C., Wittenberg T., Sticht H., Marschall M. Two isoforms of the protein kinase pUL97 of human cytomegalovirus are differentially regulated in their nuclear translocation. J. Gen. Virol. 2011, 92:638-649.
149. Wiebusch L., Hagemeier C. The human cytomegalovirus immediate early 2 protein dissociates cellular DNA synthesis from cyclin-dependent kinase activation. EMBO J. 2001, 20:1086-1098.
150. Winkler M., Stamminger T. A specific subform of the human cytomegalovirus transactivator protein pUL69 is contained within the tegument of virus particles. J. Virol. 1996, 70:8984-8987.
151. Winkler M., Rice S.A., Stamminger T. UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression. J. Virol. 1994, 68:3943-3954.
152. Winkler M., Dem S.T., Stamminger T. Functional interaction between pleiotropic transactivator pUL69 of human cytomegalovirus and the human homolog of yeast chromatin regulatory protein SPT6. J. Virol. 2000, 74:8053-8064.
153. Wolf D.G., Courcelle C.T., Prichard M.N., Mocarski E.S. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl Acad. Sci. USA 2001, 98:1895-1900.
154. Wolf D.G., Lurain N.S., Zuckerman T., Hoffman R., Satinger J., Honigman A., Saleh N., Robert E.S., Rowe J.M., Kra-Oz Z. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003, 101:463-465.
155. Zydek M., Hagemeier C., Wiebusch L. Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle. PLoS Pathog. 2010, 6:e1001096.